Table 2.
Mean and 95% confidence interval (95% CI) of mammographic total breast area (MA), dense area (MD) and mammographic density percent (MD%) in the soy and placebo group at baseline and at the end of 12 months of soy intervention
| Measure | Treatment | N | Baseline mean (95% CI) | P value between treatments at baseline | Month 12 mean (95% CI) | Ratio month 12 / baseline mean | P value-ratio within treatments | P value-ratio between treatments |
|---|---|---|---|---|---|---|---|---|
| All subjects | ||||||||
| MA | Soy | 44 | 741.7 (371.3, 1238.9) | 0.45 | 780.0 (391.8, 1300.5) | 1.03 (0.98, 1.08) | 0.58 | 0.48 |
| Placebo | 41 | 729.9 (390.7, 1174.3) | 775.9 (421.5, 1237.7) | 1.08 (1.00, 1.17) | 0.15 | |||
| MD | Soy | 44 | 80.8 (37.5, 140.4) | 0.18 | 81.7 (37.3, 143.5) | 0.98 (0.86, 1.11) | 0.50 | 0.23 |
| Placebo | 41 | 142.0 (68.6, 241.7) | 137.1 (67.3, 231.6) | 0.94 (0.80, 1.10) | 0.031 | |||
| MD% | Soy | 44 | 13.3 (9.4, 17.8) | 0.066 | 12.7 (9.0, 17.0) | 0.95 (0.84, 1.07) | 0.28 | 0.38 |
| Placebo | 41 | 19.9 (14.6, 26.0) | 18.3 (13.3, 24.1) | 0.87 (0.78, 0.98) | 0.011 | |||
|
Breast cancer patients | ||||||||
| MA | Soy | 29 | 834.0 (342.5, 1540.6) | 0.56 | 869.4 (356.2, 1608.0) | 1.01 (0.94, 1.08) | 0.48 | 0.10 |
| Placebo | 29 | 833.6 (367.1, 1488.8) | 909.3 (414.4, 1596.3) | 1.12 (1.00, 1.25) | 0.103 | |||
| MD | Soy | 29 | 77.1 (26.8, 153.2) | 0.24 | 84.9 (28.1, 172.3) | 0.97 (0.83, 1.13) | 0.86 | 0.51 |
| Placebo | 29 | 130.2 (49.6, 249.0) | 133.1 (52.3, 250.7) | 1.02 (0.84, 1.24) | 0.34 | |||
| MD% | Soy | 29 | 11.8 (7.4, 17.3) | 0.13 | 11.7 (7.4, 17.1) | 0.97 (0.84, 1.11) | 0.87 | 0.44 |
| Placebo | 29 | 17.0 (12.1, 22.7) | 16.0 (11.2, 21.7) | 0.91 (0.80, 1.04) | 0.16 | |||